Indaptus Therapeutics INDP Stock Is It a Good Entry Point Indaptus Therapeutics misses EPS views no revenue UXIN Uxin shares gain 319 percent following release of its 2025 first quarter earnings update Chevron Corporation CVX Emerging Governance Disputes in Venezuelan Operations Introduce New Portfolio Risk Considerations